OK432 versus doxycycline for treatment of macrocystic lymphatic malformations

Authors

Kevin M. Motz, Georgetown University
Katherine B. Nickley, Georgetown University
Joshua R. Bedwell, George Washington University
Buphender Yadav
Phillip C. Guzzetta, George Washington UniversityFollow
Albert K. Oh, George Washington UniversityFollow
Nancy Bauman, George Washington UniversityFollow

Document Type

Journal Article

Publication Date

2-2014

Journal

Annals of Otology, Rhinology and Laryngology

Volume

Volume 123, Issue 2

Inclusive Pages

81-88

Keywords

Anti-Bacterial Agents--administration & dosage; Antineoplastic Agents--adminsitration & dosage; Doxycycline-adminstration & dosage; Lymphatic Abnormalities--therapy; Picibanil--adminsitration & dosage; Sclerotherapy

APA Citation

Motz, K.M., Nickley, K.B., Bedwell, J.R., Yadav, B., Guzzetta, P.C. et al. (2014). OK432 versus doxycycline for treatment of macrocystic lymphatic malformations. Annals of Otology, Rhinology and Laryngology, 123(2), 81-88.

Peer Reviewed

1